Lyell Immunopharma (LYEL) Long-Term Investments (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Long-Term Investments data on file, last reported at $7.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 63.4% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 million (down 63.4% YoY), and the FY2024 full-year result was $13.0 million, down 59.33% from the prior year.
• Long-Term Investments fell to $7.0 million in Q1 2026, from $19.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $47.0 million in Q1 2022 to a low of $7.0 million in Q1 2026.
• A 5-year average of $26.6 million and a median of $19.0 million in 2024 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments tumbled 78.72% in 2023 and jumped 90.0% in 2024, its largest moves.
• Tracing LYEL's Long-Term Investments over 5 years: stood at $44.9 million in 2022, then decreased by 28.77% to $32.0 million in 2023, then plunged by 59.33% to $13.0 million in 2024, then soared by 46.0% to $19.0 million in 2025, then tumbled by 63.4% to $7.0 million in 2026.
• Business Quant data shows LYEL's Long-Term Investments at $7.0 million in Q1 2026, $19.0 million in Q3 2025, and $19.0 million in Q2 2025.